-
公开(公告)号：US20190321404A1
公开(公告)日：2019-10-24
申请号：US16474735
申请日：2017-12-29
发明人： Xiaohu FAN , Qiuchuan ZHUANG , Pingyan WANG , Lei YANG , Xiujun ZHENG , Jiaying HAO , Shaobo LIU
IPC分类号： A61K35/17 , C12N15/62 , C07K14/725 , C12N5/0735 , C07K16/32 , C07K16/30 , C12N5/0775
摘要： Disclosed herein is a novel chimeric antigen receptor and use thereof. The novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. Nucleic acid sequences of various chimeric antigen receptors are separated and purified and provided is a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.
-
公开(公告)号：US20240050474A1
公开(公告)日：2024-02-15
申请号：US18264612
申请日：2022-02-08
发明人： Ming Zeng , Weiming Wang
CPC分类号： A61K35/17 , C07K16/1045 , A61P31/18 , A61K39/4611 , A61K39/4631 , A61K39/464838 , C07K16/2866 , A61K39/464429 , A61K2239/13 , A61K2239/21
摘要： Provided are engineered cells (such as stem cells or T cells) that have a surface molecule comprising a membrane-tethered binding moiety that binds to a T cell surface antigen (such as CCR5, CD4 or CXCR4) or a HIV antigen, or a membrane tethered inhibitory moiety that inhibits the membrane fusion of HIV (such as C34). Also provided are methods of making and using these engineered cells.
-
公开(公告)号：US20240041924A1
公开(公告)日：2024-02-08
申请号：US18026297
申请日：2021-09-29
发明人： Fengyuan TANG , Wang Zhang , Yuanyuan Peng , Zhongsheng HU , Shu Wu
CPC分类号： A61K35/17 , C12N5/0636 , C07K16/2833 , C07K16/242 , C07K16/2878 , C07K16/2851 , A61K39/4611 , A61K39/4631 , A61K39/464417 , A61P35/00 , A61K2239/13
摘要： A polypeptide comprising a chimeric antigen receptor (CAR) comprising (i) an extracellular domain capable of binding to a first antigen, (ii) a transmembrane domain, and (iii) an intracellular domain; and a domain capable of binding to a second antigen expressed on the surface of a cell that can interact with a T cell, wherein the CAR and the domain are fused by a peptide linker.
-
4.发明公开公开(公告)号：US20240010745A1
公开(公告)日：2024-01-11
申请号：US18038623
申请日：2021-12-14
发明人： Ming Zeng , Huihui Zhang
CPC分类号： C07K16/2896 , A61K39/4611 , A61K39/4622 , A61K39/4631 , C07K16/2878 , C07K16/087 , C07K16/2803 , C07K16/2851 , C07K16/283 , C07K16/2866 , C07K16/2875 , A61P35/00 , A61K39/464411 , A61K39/464838 , A61K39/464419 , A61K39/464429 , A61K39/464417 , A61K2039/505 , C07K2317/732 , C07K2317/734 , C07K2317/21 , C07K2317/56 , C07K2317/569 , A61K2239/17 , A61K2239/21 , A61K2239/22 , A61K2239/48 , C07K2317/73 , C07K2317/53 , C07K2319/03 , C07K2319/02
摘要： An engineered immune cell comprising a first functional exogenous receptor capable of binding and depleting natural killer (NK) cells, and a second functional exogenous receptor, wherein the engineered immune cell has reduced MHC I on cell surface.
-
公开(公告)号：US20230257475A1
公开(公告)日：2023-08-17
申请号：US18015505
申请日：2021-07-16
发明人： Xiaohu Fan , Zhe Zhou , Hongbo PAN
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , C12N15/63 , A61P35/02
CPC分类号： C07K16/2887 , C07K16/2896 , C07K14/70517 , C07K14/7051 , C07K14/70596 , C12N15/63 , A61P35/02 , C07K2319/03 , C07K2317/569 , C07K2317/565
摘要： The present disclosure provides chimeric antigen receptors targeting CD20, CD19 and/or CD22. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
-
公开(公告)号：US20230250184A1
公开(公告)日：2023-08-10
申请号：US18015506
申请日：2021-07-16
发明人： Xiaohu Fan , Zhe Zhou , Qiuchuan ZHUANG , Xu Fang , Yue HAN , Youguo PENG , Hefei HOU
CPC分类号： C07K16/2896 , C12N15/63 , A61P35/00 , C07K2317/565 , C07K2317/569 , C07K2319/02 , C07K2319/03 , C07K2317/53
摘要： The present disclosure provides single domain antibodies that bind to CD22, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
-
公开(公告)号：US11673954B2
公开(公告)日：2023-06-13
申请号：US16764411
申请日：2018-11-13
发明人： Yafeng Zhang , Shu Wu , Shuai Yang , Chuan-Chu Chou
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , A61K39/395 , A61K45/06
CPC分类号： C07K16/2827 , A61K39/3955 , A61K45/06 , A61P35/00 , A61K2039/505 , C07K2317/21 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/569 , C07K2317/76 , C07K2317/92
摘要： The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-L1. Also provided are methods of making and using these constructs.
-
公开(公告)号：US11472881B2
公开(公告)日：2022-10-18
申请号：US16341034
申请日：2017-10-10
发明人： Yafeng Zhang , Shu Wu , Shuai Yang , Chuan-Chu Chou
摘要： The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Also provided are methods of making and using these constructs.
-
公开(公告)号：US20220265709A1
公开(公告)日：2022-08-25
申请号：US17251310
申请日：2019-06-19
发明人： Huihui Zhang , Fangliang Zhang , Tao Zhao , Ming Zeng , Yafeng Zhang , Wang Zhang , Shu WU , Qi Pan , Shuai Yang
摘要： A system for inducing activity of immune cells, comprises a chimeric antigen receptor, a T cell receptor, and various combinations thereof.
-
公开(公告)号：US20220144960A1
公开(公告)日：2022-05-12
申请号：US17312497
申请日：2019-12-26
发明人： Shuai Yang , Sujuan Wang , Chenyu Shu , Yuanyuan Peng , Chen Hu , Shu Wu
IPC分类号： C07K16/28 , A61K35/17 , A61P35/00 , C07K14/725 , C12N5/0783
摘要： CD30-binding moieties, chimeric antigen receptors (CARs) having these CD30-binding moieties, and uses thereof are provided. Polynucleotides encoding the CD30-binding moieties and CARs, compositions comprising CD30-binding moieties and CARs, genetically modified immune cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30-expressing cancer or tumor in a subject in need thereof are also provided herein.
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.028 秒)
